How should a patient with a positive Clostridioides difficile toxin A/B assay but a negative enzyme immunoassay be managed?

Management of discordant C. difficile tests (toxin A/B positive but EIA negative)

Treat as true C. difficile infection if the patient has clinically significant diarrhea (≥3 unformed stools in 24 hours) and risk factors; do not delay therapy for repeat testing. 1

• Rationale and hierarchy of evidence
  • Guideline priority: IDSA/SHEA recommend toxin detection within a multistep algorithm; toxin-positive results correlate with higher complications and mortality and warrant treatment, while NAAT-only positives may represent colonization 1. Morbidity/mortality signal is strongest in toxin-positive groups 1.
  • Pitfall: Stand‑alone toxin EIAs have imperfect sensitivity; missing toxin can occur despite true disease, especially in severe cases. Guidelines discourage routine repeat testing within 7 days unless clinical status worsens 1.

Algorithm (prioritizing morbidity, mortality, QoL)

1. Confirm clinical criteria before acting on labs

   • Diarrhea: ≥3 unformed stools in 24 h; recent antibiotics, healthcare exposure, age >65, immunosuppression, PPI use.
   • Exclude formed stools/asymptomatic carriage (do not test or treat) 1.

2. Interpret discordant results

   • If any toxin assay is positive (even if another EIA reads negative), classify as likely CDI (true toxin production) and treat; toxin positivity predicts worse outcomes and benefits from therapy 1.
   • If only NAAT positive and toxin negative, be cautious—higher chance of colonization; treat only with strong clinical evidence of disease or severity markers (fever >38.5°C, leukocytosis, rising creatinine, hypoalbuminemia), as these predict complications 2. This nuance supports not over-treating colonization but promptly treating true disease to reduce mortality/QoL loss.

3. Start appropriate therapy immediately (no repeat testing delays)

   • Nonfulminant CDI: oral fidaxomicin preferred; oral vancomycin acceptable if fidaxomicin unavailable.
   • Fulminant (hypotension, ileus, megacolon): oral/NG vancomycin plus IV metronidazole; surgical consult early. Severe presentations can be toxin-EIA negative early—treat the patient, not the delayed/insensitive assay 1. Case experience and observational data highlight risk of waiting in severe disease 2, 3.

4. Infection control now

   • Contact precautions, hand hygiene with soap and water, environmental sporicidal cleaning to prevent transmission, as discordant cases can still shed spores 4.

5. Do not repeat testing within 7 days unless clear clinical worsening or recurrence after resolution; do not test for cure 1.

Nuances, pitfalls, and how to avoid harm

• Common pitfall: Treating NAAT+/toxin− without symptoms—risks overtreatment; avoid unless strong clinical evidence of CDI or severity markers 1, 2.
• Opposite pitfall: Withholding therapy when any toxin test is positive because another EIA is negative—this increases risk of complications and mortality; treat toxin-positive discordance as CDI 1.
• In IBD flares with PCR+/toxin−, escalation of IBD therapy is often needed; toxin positivity and high CRP help point to true CDI requiring antibiotics 5.
• Imaging showing colitis supports treatment in discordant cases and is associated with real-world treatment decisions 6.

Evidence strengths and divergences

• IDSA/SHEA guidelines (Clinical Infectious Diseases, 2018) guide testing algorithms and link toxin positivity to worse outcomes—highest quality and frames management 1.
• Observational cohorts show NAAT+/toxin− generally have fewer CDI complications than toxin+; but severe clinical features predict complications even when toxin EIA is negative—supporting immediate treatment when severity is present to protect mortality/QoL 2.